Evidence map›Paper›PMID 32557377›Full record

ArticleInternational urology and nephrology2020

Serum NGAL, KIM-1, IL-18, L-FABP: new biomarkers in the diagnostics of acute kidney injury (AKI) following invasive cardiology procedures.

Magdalena Zdziechowska, Anna Gluba-Brzózka, Adam R Poliwczak, Beata Franczyk, Michał Kidawa, Marzenna Zielinska, Jacek Rysz

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International urology and nephrology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Magdalena ZdziechowskaDepartment of Nephrology, Hypertension and Family Medicine, Medical University of Lodz, Zeromskiego 113, 90-549, Lodz, Poland.
Anna Gluba-BrzózkaDepartment of Nephrology, Hypertension and Family Medicine, Medical University of Lodz, Zeromskiego 113, 90-549, Lodz, Poland. aniagluba@yahoo.pl.ORCID http://orcid.org/0000-0003-3322-5655
Adam R PoliwczakDepartment of Human Physiology, Chair of Experimental and Clinical Physiology, Medical University of Lodz, Lodz, Poland.
Beata FranczykDepartment of Nephrology, Hypertension and Family Medicine, Medical University of Lodz, Zeromskiego 113, 90-549, Lodz, Poland.
Michał KidawaDepartment of Intensive Cardiac Therapy, Central Teaching Hospital of the Medical University of Lodz, Lodz, Poland.
Marzenna ZielinskaDepartment of Intensive Cardiac Therapy, Central Teaching Hospital of the Medical University of Lodz, Lodz, Poland.
Jacek RyszDepartment of Nephrology, Hypertension and Family Medicine, Medical University of Lodz, Zeromskiego 113, 90-549, Lodz, Poland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe aim of this study was to assess the levels of selected markers in patients who underwent planned or emergency coronary angiography and to examine if they correlated with the occurrence of AKI.

methodsThe study included 52 patients who underwent planned or emergency coronary angiography and received contrast agent. Serum levels of markers (NGAL, L-FABP, KIM-1, IL-18) were analyzed in all patients using ELISA tests, at baseline, after 24 and 72 h from angiography.

results9.62% of patients developed CI-AKI. No significant differences were observed between markers levels in patients who developed CI-AKI and those who did not. After 24 h, serum levels of IL-18 were higher in patients with CI-AKI, however, this difference was on the verge of significance. Increase in serum NGAL, KIM-1 and IL-18 was observed after 24 h. Serum levels of biomarkers were insignificantly higher in group with CI-AKI. Significant changes in levels in time (baseline vs. 24 h vs. 72 h) were observed only for NGAL [157.9 (92.4-221.0) vs. 201.8 (156.5-299.9) vs. 118.5 (73.4-198.7); p < 0.0001]. No significant correlations were observed between the decrease in eGFR or the increase in creatinine and biomarkers level.

conclusionObtained results do not allow for the indication of efficient AKI biomarkers. Their further validation in large studies of CI-AKI patients is required.

Indexed as

Coronary AngiographyAcute Kidney InjuryAgedBiomarkersFatty Acid-Binding ProteinsFemaleHepatitis A Virus Cellular Receptor 1HumansInterleukin-18Lipocalin-2MaleMiddle AgedTime FactorsBiomarkersFABP1 protein, humanFatty Acid-Binding ProteinsHAVCR1 protein, humanHepatitis A Virus Cellular Receptor 1Interleukin-18Lipocalin-2Acute kidney injuryBiomarkersContrast-inducedIL-18KIM-1L-FABPNGAL

Identifiers

PMID32557377
PMCPMC7575457

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.